Shimoyama Shouji, Mochizuki Yoshino, Kusada Osamu, Kaminishi Michio
Department of Gastrointestinal Surgery, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Int J Oncol. 2002 Sep;21(3):643-8.
We investigated supra-additive cytotoxic effects of 5-fluorouracil (5FU) on gastric and colon cancer cells with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in vitro. p53 wild- and mutant-type gastric and colon cancer cell lines were treated by 5FU alone, TRAIL alone, and a combination of 5FU and TRAIL, and cell viability after each treatment was determined by MTT assay. The p53 wild-type cells were more sensitive to 5FU alone or to TRAIL alone than p53 mutant-type cells. The cell growth inhibitory effects of the combined treatment were supra-additive and more significant in proportion to the increasing concentrations of TRAIL as compared with 5FU alone both in p53 wild- and mutant-type cells. Furthermore, TRAIL could cause a decrease in 5FU IC(50) to within the range of clinically relevant doses, particularly in p53 wild-type cells. This is the first demonstration of the supra-additive antitumor activity of 5FU with TRAIL on gastric cancer cells, giving evidence that TRAIL can reduce the requirement for 5FU that ultimately results in minimizing risks for systemic side effects while increasing the antitumor activity of 5FU, suggesting the clinical applicability of this combination for gastric and colon cancers.
我们在体外研究了5-氟尿嘧啶(5FU)与肿瘤坏死因子相关凋亡诱导配体(TRAIL)联合对胃癌和结肠癌细胞的超相加细胞毒性作用。分别用单独的5FU、单独的TRAIL以及5FU与TRAIL联合处理p53野生型和突变型胃癌及结肠癌细胞系,通过MTT法测定每种处理后的细胞活力。p53野生型细胞比p53突变型细胞对单独的5FU或单独的TRAIL更敏感。联合处理的细胞生长抑制作用是超相加的,并且与单独使用5FU相比,在p53野生型和突变型细胞中,随着TRAIL浓度的增加,这种作用更显著。此外,TRAIL可使5FU的半数抑制浓度(IC50)降低至临床相关剂量范围内,尤其是在p53野生型细胞中。这是首次证明5FU与TRAIL联合对胃癌细胞具有超相加抗肿瘤活性,表明TRAIL可降低对5FU的需求,最终在增加5FU抗肿瘤活性的同时将全身副作用风险降至最低,提示这种联合疗法在胃癌和结肠癌治疗中的临床适用性。